Cabenuva (cabotegravir + rilpivirine) vs Apretude (cabotegravir extended-release injectable suspension)
Cabenuva (cabotegravir + rilpivirine) vs Apretude (cabotegravir extended-release injectable suspension)
Cabenuva (cabotegravir + rilpivirine) is a long-acting, injectable regimen approved for the treatment of HIV-1 in adults who are virologically suppressed on a stable antiretroviral regimen. It is administered once monthly or once every two months after an initial oral lead-in period to ensure tolerability to the medications. In contrast, Apretude (cabotegravir extended-release injectable suspension) is used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in individuals at risk, and it is administered once every two months after an initial oral lead-in period and two initial one-month apart injections. When deciding between the two, it is important to consider the intended use: treatment of existing HIV-1 infection with Cabenuva versus prevention of HIV-1 acquisition with Apretude.
Difference between Cabenuva and Apretude
Metric | Cabenuva (cabotegravir + rilpivirine) | Apretude (cabotegravir extended-release injectable suspension) |
---|---|---|
Generic name | Cabotegravir and Rilpivirine | Cabotegravir |
Indications | Treatment of HIV-1 in adults | Pre-exposure prophylaxis (PrEP) of HIV infection |
Mechanism of action | Integrase inhibitor (cabotegravir) and non-nucleoside reverse transcriptase inhibitor (rilpivirine) | Integrase inhibitor |
Brand names | Cabenuva | Apretude |
Administrative route | Intramuscular injection | Intramuscular injection |
Side effects | Injection site reactions, fever, fatigue, headache, musculoskeletal pain | Injection site reactions, fever, fatigue, headache |
Contraindications | Previous hypersensitivity reaction to cabotegravir or rilpivirine | Previous hypersensitivity reaction to cabotegravir |
Drug class | Antiretroviral combination | Antiretroviral |
Manufacturer | ViiV Healthcare | ViiV Healthcare |
Efficacy
Efficacy of Cabenuva for HIV/AIDS
Cabenuva, a combination of cabotegravir and rilpivirine, is a long-acting, injectable regimen approved for the treatment of HIV-1 infection in adults. This regimen is designed for those who are virologically suppressed on a stable antiretroviral regimen, have no history of treatment failure, and are not resistant to cabotegravir or rilpivirine. Clinical trials have demonstrated that Cabenuva is effective in maintaining viral suppression in patients with HIV-1. The ATLAS and FLAIR studies, pivotal phase 3 trials, showed that Cabenuva was as effective as continuing a daily oral regimen in maintaining viral suppression over a 48-week period.
Efficacy of Apretude for HIV/AIDS Prevention
Apretude (cabotegravir extended-release injectable suspension) is the first long-acting injectable regimen approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents. Apretude is administered as an intramuscular injection once every two months after an initial loading dose. The efficacy of Apretude for HIV prevention was demonstrated in two major clinical trials, HPTN 083 and HPTN 084. These trials found that Apretude was more effective than daily oral emtricitabine/tenofovir disoproxil fumarate tablets in preventing HIV acquisition.
Comparative Efficacy and Considerations
When comparing the efficacy of Cabenuva and Apretude, it is important to note that they serve different purposes within the realm of HIV/AIDS management. Cabenuva is used as a treatment for individuals who are already HIV-positive, while Apretude is used to prevent the acquisition of HIV in HIV-negative individuals at risk for infection. Both medications leverage the long-acting nature of cabotegravir to provide options that reduce the burden of daily pill-taking, which can enhance adherence and overall treatment or prevention success.
Conclusion
In conclusion, both Cabenuva and Apretude have shown high efficacy in their respective roles for the management and prevention of HIV/AIDS. Cabenuva offers a monthly treatment alternative for those with viral suppression, while Apretude provides a long-acting option for PrEP, expanding the tools available to combat the HIV epidemic. Ongoing research and post-marketing surveillance continue to evaluate the long-term efficacy and safety profiles of these medications.
Regulatory Agency Approvals
Cabenuva
Apretude
Access Cabenuva or Apretude today
If Cabenuva or Apretude are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us